The Center will consolidate all known and emerging knowledge about how proteins behave into "The Protease Pathway Interrogation Platform ('PIPP')". The platform, PIPP, will be the product of a multi-disciplinary team, including the Burnham Institute's Guy Salvesen, Ph.D., an expert on proteases and co-director of the center; Alex Strongin, Ph.D., a Professor at the Institute's Inflammation and Infectious Disease Center; Adam Godzik, Ph.D., Director of the Institute's Systems Biology Program, and Andrei Osterman, Ph.D., Professor in that same program. Collaborators on this effort include Drs. Mathew Bogyo from Stanford University, Bonnie Sloane of Wayne State University, and Lisa Coussens from the University of California at San Francisco.
Why study proteolytic pathways? Proteolysis, or how proteins break down, regulates the four fundamental aspects of cell behavior: division, death, differentiation, and motility. Understanding this process is critical to designing new therapies based on promoting or inhibiting cellular behaviors.
A particular strength of the Center is its emphasis on the use of activity-based proteomics to profile protease function. This approach, developed by Dr. Bogyo at Stanford, marks an innovation over other proteomics strategies because the activity-based approach reports on protease activity, as opposed to just abundance.
In practical terms, Dr. Smith envisions that technology developed within the Center "should ultimately help define the physiologic and pathophysiologic role of every human protease." Equally as significant, the Center will devise computational methods for predicting the behavior of entire biochemical pathways that connect to proteases.
Another outcome of research at the Center will be the development of a platform for screening small molecular libraries against all proteases encoded by the genome. Indeed, earlier this spring, Dr. Smith published results in the journal Cancer Research from his first proteomics-based assay which yielded the surprising result that Orlistat, a drug approved by the FDA for treatment of obesity, inhibited prostate cancer.
The Center on Proteolytic Pathways is the newest plank in the Burnham Institute's Drug Discovery Initiative, the Institute's commitment to building up the intellectual and instrumental infrastructure needed to close the gap between discovery and application of new knowledge.
The Burnham's "Center on Proteolytic Pathways" is one of two new centers launching the "National Technology Centers Network and Pathways Directory" included in the "NIH Roadmap for Medical Research", implemented by NIH Director Elias A. Zerhouni. Designated technology centers will be focused on a biological theme and aim to shorten the pathway from medical discovery and development of technology needed to develop applications for this new knowledge.
"These tools will give us a completely new way of looking at complex biological processes, allowing us to actually watch them in action," said NIH Director Elias A. Zerhouni, M.D. "As the centers refine the technologies, these valuable resources will be made available to hundreds of investigators across the country who are working in every disease area."
The Burnham Institute is an independent, nonprofit, public benefit organization dedicated to basic biomedical research principally in the areas of cancer, neurosciences, aging, infectious and inflammatory diseases. The Institute ranks consistently among the world's most influential research organizations for the impact of its research in analyses conducted annually by the Institute for Scientific Information. To learn more about The Burnham Institute, please visit http://www.burnham.org.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.